Lyndsey Hanson

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 182 citations

Medicine, Oncology, Pharmacology +16

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson et al. · Molecular Cancer Therapeutics · 2014 · 99 citations · Full text

Medicine, Oncology, Pharmacology +13

Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS^G12C

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2020 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)

Richard A. Ward, Mark J. Anderton, Paul A. Bethel et al. · Journal of Medicinal Chemistry · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logié et al. · Molecular Cancer Therapeutics · 2015 · 73 citations

Medicine, Oncology, Pharmacology +17